CCO Annual Update
HIV/AIDS Annual Update 2007
Viral and Host Factors Affecting HIV-1 Transmission
|
Module 1 of 10
|
|
|
|
 Julie Overbaugh, PhD, reviews viral and host factors that influence transmission of HIV-1 and discusses the potential clinical impact of HIV superinfection. Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the viral factors that influence transmission of HIV-1
- Describe host factors that may positively or negatively influence the transmission of HIV-1
- Discuss the potential clinical impact and risk of reinfection in HIV-infected people
|
Mechanisms of Immune Deficiency in HIV Infection
|
Module 2 of 10
|
|
|
|
Michael M. Lederman, MD, discusses data from human and animal models that have led to hypotheses on the mechanisms resulting in immune deficiency that occurs after HIV infection. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current knowledge about the determinants of CD4+ T-cell loss in HIV infection
- Discuss the relationship between HIV replication and CD4+ T-cell losses in HIV infection
- Summarize the relationship between immune activation and immune deficiency in HIV infection
|
Timing and Choice of Therapy in Treatment-Naive Patients
|
Module 3 of 10
|
|
|
|
Roy M. Gulick, MD, MPH, presents a review of the literature that supports current paradigms for first-line therapy regimens, including guideline recommendations on when to start. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the most appropriate timing for the initiation of antiretroviral treatment
- Identify antiretroviral therapy approaches for treatment-naive HIV-infected patients
- Describe future potential developments in standardized ART
|
New Drugs for Treatment-Experienced Patients
|
Module 4 of 10
|
|
|
|
Joel E. Gallant, MD, MPH, reviews current data on the use of new agents for experienced patients and offers perspective on how these drugs may be incorporated in current treatment paradigms—or how new paradigms may develop. Learning Objectives
Upon completion of this activity, participants should be able to:
- List agents in current classes and novel classes that are under clinical development for treatment-experienced patients
- Discuss data on the use of new agents in drug-resistant patients
- Describe the principles guiding the use of new antiretroviral agents in the management of treatment-experienced patients
|
Inhibitors of Human Immunodeficiency Virus Type I Integration
|
Module 5 of 10
|
|
|
|
Daria J. Hazuda, PhD, describes the mode of action of the integrase inhibitors that are currently in development, raltegravir and elvitegravir Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of integrase in HIV-1 replication
- Identify the mechanism of integrase inhibitors and how inhibitors may lead to resistant mutations
- Discuss the future potential of integrase inhibitors
|
Update on HIV/HBV Coinfection
|
Module 6 of 10
|
- Marion G. Peters, MD, FRACP
|
|
|
Marion G. Peters, MD, presents the latest data and analysis on the epidemiology and treatment of patients who are coinfected with HIV and HBV. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the effects of HIV on the clinical course of hepatitis B virus (HBV) infection
- Discuss the effects of HBV on the clinical course of HIV infection
- Explain approaches to the treatment of HIV/HBV coinfection
|
Management of Pregnancy in HIV-Infected Women
|
Module 7 of 10
|
|
|
|
Kathleen E. Squires, MD, reviews the most recent DHHS guidelines on HIV treatment during pregnancy and discusses approaches to conception for both HIV-concordant and HIV-discordant couples. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss information from the US Department of Health and Human Services perinatal treatment guidelines on counseling and care of HIV-infected women of child-bearing potential
- Describe approaches to conception for HIV-concordant and HIV-discordant couples
- Identify preferred antiretroviral agents for use during pregnancy
|
Aging and the HIV-Infected Patient
|
Module 8 of 10
|
|
|
|
William G. Powderly, MD, discusses the epidemiology, treatment, and comorbidity issues that are unique to HIV-infected patients 50 years of age or older. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the increasing prevalence of HIV/AIDS in the older population
- Summarize HIV risk factors associated with older individuals
- Discuss the impact of comorbidities when identifying optimal treatment strategies for older HIV-infected patients
|
An HIV-1–Specific Microbicide Is a Public Health Priority
|
Module 9 of 10
|
|
|
|
John P. Moore, PhD, discusses the importance of a practical microbicide in the prevention of HIV transmission and also reviews data on several investigational microbicides with varying mechanisms of action. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanism of action of several investigational microbicides
- Specify the practical and desired characteristics of microbicides
- Discuss future directions in the design and application of microbicides
|
HIV and TB in Sub-Saharan Africa: Learning From a Catastrophic Collision
|
Module 10 of 10
|
|
|
|
Richard E. Chaisson, MD, an HIV treater and epidemiologist, describes how HIV treaters and TB treaters can learn from each other in battling this dual epidemic. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the epidemiology of HIV/AIDS and tuberculosis (TB) in sub-Saharan Africa
- Discuss the impact of TB on the HIV epidemic and the effect of HIV on the TB epidemic
- List a strategy that HIV care providers can adopt from TB treatment paradigms and a strategy that TB care providers can adopt from HIV treatment paradigms
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|